Prezatide

Summary

Prezatide (copper‑tri­peptide‑1, also known as GHK‑Cu) is a copper‑binding peptide approved for prescription use in wound‑repair and regenerative applications. It is administered by subcutaneous injection or as a topical formulation and is incorporated into several combination products aimed at stimulating hair growth, reducing scar tissue, and improving scalp conditions such as dandruff. Clinical and pre‑clinical studies report enhanced hair density, decreased scar visibility, and accelerated wound‑closure, although most data derive from open‑label or animal investigations.

Mechanism of Action

Copper‑tri­peptide‑1 binds copper ions and facilitates their delivery to skin cells, where the complex modulates extracellular‑matrix remodeling and growth‑factor pathways. In fibroblasts it reduces secretion of the profibrotic cytokine TGF‑β1 and can increase production of basic fibroblast growth factor (bFGF). The peptide also promotes angiogenesis and keratinocyte proliferation, supporting hair‑follicle health and wound repair. When combined with other growth factors, it may synergistically enhance cellular proliferation and extracellular‑matrix synthesis, contributing to observed regenerative effects.

What the Research Shows

A first‑in‑human pilot study injected a hair‑growth formulation containing copper‑tripeptide‑1 alongside VEGF, bFGF, IGF‑1, KGF and thymosin β4 into 1,000 patients; 83 % showed reduced hair fall and a statistically significant rise in total hair count after eight sessions. In vitro work with normal and keloid fibroblasts demonstrated that copper‑tripeptide‑1 lowered TGF‑β1 secretion, suggesting anti‑scar potential. Animal studies of QR 678/QR 678 Neo injections (including copper‑tripeptide‑1) produced localized hair growth in mice without cytotoxicity. A 15‑day scalp regimen combining a hydroxy‑acid scrub with a copper‑tripeptide‑1 serum reduced dandruff scores by 61 % and increased scalp hydration by 76 %. A scar‑fader gel containing copper‑tripeptide‑1 improved scar scores by up to 27 % over 45 days. Finally, copper‑tripeptide‑1 conjugated silver nanoparticles achieved a 2.8‑fold increase in in‑vitro wound closure versus peptide alone.

Reported Benefits

Evidence suggests that copper‑tripeptide‑1 can contribute to increased hair density and reduced shedding when delivered intradermally with other growth factors. In vitro and clinical scar studies indicate a reduction in TGF‑β1‑mediated fibrosis, translating into visible scar softening. Topical formulations have shown rapid improvement in dandruff severity, scalp hydration, and hair thickness. When used to cap silver nanoparticles, the peptide enhances wound‑closure rates in cell‑based assays, supporting its role in accelerating tissue repair.

Limitations of the Evidence

Most data come from open‑label, single‑arm or animal studies; there are no large, randomized controlled trials isolating copper‑tripeptide‑1’s effect. The hair‑growth and scalp‑dandruff studies used multi‑ingredient blends, making it difficult to attribute outcomes solely to the peptide. Sample sizes, follow‑up durations, and reporting of comparator groups are limited, and long‑term safety beyond the study periods remains uncharacterized. Regulatory approval reflects prescription status but does not guarantee efficacy for all listed indications.

Safety Considerations

Across the reported studies, intradermal injections of copper‑tripeptide‑1‑containing formulations were well tolerated, with no serious systemic adverse events noted. Topical applications, including serums and gels, reported no local irritation or allergic reactions. The peptide‑silver nanoparticle conjugates were evaluated in vitro only, so human safety data are lacking for that format. Caution is advised for patients with known copper hypersensitivity, and standard injection‑site monitoring should be performed.

How It Is Administered

Prezatide is supplied for subcutaneous or intradermal injection, typically mixed in a sterile injectable vehicle and administered at intervals ranging from weeks to months in clinical protocols. Topical products such as serums, gels, or combined scrub‑serum kits are applied to the scalp or skin surface, usually once or twice daily, depending on the formulation. Both routes are used in combination with other active ingredients in the marketed preparations.

Routes of Administration

Goals & Uses

• Hair growth promotionDermatology / TrichologyLow
• Oral mucosal wound healingOral MedicineModerate
• Collagen synthesis stimulationDermatology / Anti AgingModerate
• Wound healing accelerationRegenerative MedicineModerate
• Skin repair and anti-agingDermatologyModerate
• Anti-inflammatory effectsInflammationLow

Contraindications

• Active infection at application siteInfectiousModerate
• Hypersensitivity to copper or peptide componentsAllergyHigh
• Wilson's diseaseMetabolic DisorderHigh

Adverse Effects

• Local skin irritationDermatologicalUncommon
• Contact dermatitisDermatologicalRare
• Copper accumulation (theoretical)MetabolicRare

Drug Interactions

• PenicillamineModerate
• Zinc supplementsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Patients with copper metabolism disordersMetabolicAbsolute

Regulatory Status

• European UnionUnapprovedNot approved as a drug in the EU; used as a cosmetic ingredient under INCI name Copper Tripeptide-1.
• United StatesInvestigationalInvestigated by FDA as a topical drug for oral mucosal wound healing; not broadly approved as a pharmaceutical. Present in OTC cosmetics as Copper Tripeptide-1.
• United KingdomUnapprovedNo regulatory drug approval in the UK; available as a cosmetic ingredient.

Prezatide copper acetate was investigated as a topical wound healing agent. It received some regulatory attention in the US for oral mucosal injuries. It is present in some cosmetic and dermatological products under the INCI name Copper Tripeptide-1. Its regulatory status as a drug is limited; it is not broadly FDA-approved as a pharmaceutical drug for systemic use.

Evidence & Sources

• Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study
  Journal ArticleLowKapoor R, Shome D2018-01-01T00:00:00.000000Z
• The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model
  Journal ArticleLowMcCormack MC, Nowak KC, Koch RJ2001-01-01T00:00:00.000000Z
• An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults
  Journal ArticleLowPatel MN, et al.2024-01-01T00:00:00.000000Z
• QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study
  Journal ArticleLowKapoor R, et al.2020-01-01T00:00:00.000000Z
• Effect of Peptides on the Synthesis, Properties and Wound Healing Capacity of Silver Nanoparticles
  Journal ArticleLowPapaioannou A, et al.2023-01-01T00:00:00.000000Z
• Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars
  Journal ArticleLowPatel MN, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions